TELAHealthcare · Medical DevicesThe 5 Wall Street analysts covering TELA Bio, Inc. hold a median 12-month price target of $2 — +209.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 27 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores TELA Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (86): Smaller than most of the companies we track.
Issuance (9): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on TELA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +209.5% from it.
Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 Mar 2026 | Citizens | Maintains | Market Outperform | $5.00 → $3.00 |
| 25 Mar 2026 | Canaccord Genuity | Maintains | Buy | $4.00 → $2.00 |
| 25 Mar 2026 | Lake Street | Maintains | Buy | $3.00 → $2.00 |
| 25 Mar 2026 | Piper Sandler | Maintains | Neutral | $1.25 → $1.00 |
| 1 Dec 2025 | Lake Street | Maintains | Buy | — |
| 18 Nov 2025 | Canaccord Genuity | Maintains | Buy | — |
| 14 Nov 2025 | Citizens | Maintains | Market Outperform | — |
| 14 Nov 2025 | Piper Sandler | Reiterates | Neutral | — |
| 21 Mar 2025 | Canaccord Genuity | Maintains | Buy | — |
| 21 Mar 2025 | Citizens Capital Markets | Maintains | Market Outperform | — |
| 21 Mar 2025 | Piper Sandler | Downgrade | Neutral | — |
| 8 Nov 2024 | Piper Sandler | Maintains | Overweight | — |
| 4 Oct 2024 | Canaccord Genuity | Maintains | Buy | — |
| 13 Aug 2024 | Canaccord Genuity | Maintains | Buy | — |
| 13 Aug 2024 | JMP Securities | Maintains | Market Outperform | — |
| 13 Aug 2024 | Lake Street | Maintains | Buy | — |
| 13 Aug 2024 | Piper Sandler | Maintains | Overweight | — |
| 25 July 2024 | Canaccord Genuity | Maintains | Buy | — |
| 10 May 2024 | Piper Sandler | Reiterates | Overweight | — |
| 22 Mar 2024 | JMP Securities | Reiterates | Market Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TELA appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 81% of US stocks
Cheaper than 87% of US stocks
Cheaper than 97% of US stocks
Cheaper than 70% of US stocks
Higher than 20% of US stocks
Higher than 39% of US stocks
Higher than 79% of US stocks
Higher than 17% of US stocks
Higher than 10% of US stocks
Higher than 2% of US stocks
Higher than 13% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own TELA Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
TELA Bio, Inc. released its Q2 2026 earnings call transcript, published via Seeking Alpha. The transcript covers the company's second-quarter financial results and management discussion.
Why it matters — A TELA watcher would review this transcript for management commentary and financial detail on the company's Q2 2026 performance.
TELA Bio reported a second-quarter loss of $0.20 per share, wider than the Zacks Consensus Estimate of a $0.17 loss, and lagged revenue estimates. The result compares with a $0.22 per share loss in the same period a year ago.
Why it matters — The results came in below analyst expectations for both earnings and revenue, providing an update on the company's recent financial performance for TELA watchers.
TELA Bio announced inducement grants under Nasdaq Rule 5635(c)(4), approving stock options to purchase 2,370,000 shares and restricted stock units covering 500,000 shares for newly-hired CEO Heather Getz (grant date August 3, 2026). The Compensation Committee also approved restricted stock units covering 95,500 shares for 11 newly-hired employees (grant date August 4, 2026), granted as an inducement material to their acceptance of employment.
Why it matters — The announcement marks the compensation structure tied to the onboarding of a new CEO and 11 new employees, signalling executive and workforce additions at TELA Bio.
TELA Bio announced that its Board of Directors has appointed Heather Getz as Chief Executive Officer and Director, effective August 4, 2026.
Why it matters — A change in CEO leadership can signal a new strategic direction for the company, and Heather Getz's appointment is a key development for investors and stakeholders tracking TELA Bio's management team.
TELA Bio announced it will participate in the Canaccord Genuity 46th Annual Growth Conference.
Why it matters — A conference appearance provides TELA Bio with a platform to present its soft-tissue reconstruction solutions to potential investors and industry analysts.
The 5 Wall Street analysts covering TELA Bio, Inc. have a median 12-month price target of $2, with estimates ranging from $1 to $3. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering TELA Bio, Inc., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks TELA Bio, Inc. 27 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, TELA Bio, Inc. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (86 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +209.5% from the last close, and Ticker Nerd's factor model ranks TELA Bio, Inc. 27 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering TELA Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TELA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $3 over the next 12 months.
TELA Bio, Inc. returned -62.4% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Tela Bio Inc. is a company specialized in the development and commercialization of innovative soft tissue reconstruction solutions.
The most recent item we track (Seeking Alpha, 11 Aug 2026): "TELA Bio, Inc. (TELA) Q2 2026 Earnings Call Transcript". TELA Bio, Inc. released its Q2 2026 earnings call transcript, published via Seeking Alpha. The transcript covers the company's second-quarter financial results and management discussion.
Tela Bio Inc. is a company specialized in the development and commercialization of innovative soft tissue reconstruction solutions. The company's primary focus is on providing advanced medical products designed to improve the performance of soft tissue repair options, particularly in the fields of general surgery and hernia repair. Tela Bio Inc.'s portfolio includes its proprietary OviTex and OviTex PRS product lines, which incorporate biologic and synthetic materials to offer better performance and clinical outcomes compared to traditional materials. In the healthcare sector, Tela Bio operates at the intersection of biotechnology and medical devices, addressing the critical needs of surgeons and patients for more efficient and reliable surgical repairs. Tela Bio's innovative solutions are contributing to enhanced patient care, offering reduced complications and better integration with the body’s natural tissue. Headquartered in the United States, the company plays a significant role in the medical field by pushing the boundaries of soft tissue reconstruction technologies, which are vital for enhancing surgical techniques and outcomes.
CEO Ms. Heather C. Getz C.P.A., M.B.A. · 218 employees · United States · https://www.telabio.com